Last reviewed · How we verify
IPH5201
At a glance
| Generic name | IPH5201 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (PHASE2)
- IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPH5201 CI brief — competitive landscape report
- IPH5201 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI